Cargando…

Pexiganan in Combination with Nisin to Control Polymicrobial Diabetic Foot Infections

Diabetic foot ulcers (DFUs) are major complications of Diabetes mellitus being responsible for significant morbidity and mortality. DFUs frequently become chronically infected by a complex community of bacteria, including multidrug-resistant and biofilm-producing strains of Staphylococcus aureus and...

Descripción completa

Detalles Bibliográficos
Autores principales: Gomes, Diana, Santos, Raquel, S. Soares, Rui, Reis, Solange, Carvalho, Sandra, Rego, Pedro, C. Peleteiro, Maria, Tavares, Luís, Oliveira, Manuela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7148459/
https://www.ncbi.nlm.nih.gov/pubmed/32244862
http://dx.doi.org/10.3390/antibiotics9030128
_version_ 1783520597394849792
author Gomes, Diana
Santos, Raquel
S. Soares, Rui
Reis, Solange
Carvalho, Sandra
Rego, Pedro
C. Peleteiro, Maria
Tavares, Luís
Oliveira, Manuela
author_facet Gomes, Diana
Santos, Raquel
S. Soares, Rui
Reis, Solange
Carvalho, Sandra
Rego, Pedro
C. Peleteiro, Maria
Tavares, Luís
Oliveira, Manuela
author_sort Gomes, Diana
collection PubMed
description Diabetic foot ulcers (DFUs) are major complications of Diabetes mellitus being responsible for significant morbidity and mortality. DFUs frequently become chronically infected by a complex community of bacteria, including multidrug-resistant and biofilm-producing strains of Staphylococcus aureus and Pseudomonas aeruginosa. Diabetic foot infections (DFI) are often recalcitrant to conventional antibiotics and alternative treatment strategies are urgently needed. Antimicrobial Peptides (AMPs), such as pexiganan and nisin, have been increasingly investigated and reported as effective antimicrobial agents. Here, we evaluated the antibacterial potential of pexiganan and nisin used in combination (dual-AMP) to control the growth of planktonic and biofilm co-cultures of S. aureus and P. aeruginosa clinical strains, co-isolated from a DFU. A DFU collagen three-dimensional (3D) model was used to evaluate the distribution and efficacy of AMPs locally delivered into the model. The concentration of pexiganan required to inhibit and eradicate both planktonic and biofilm-based bacterial cells was substantially reduced when used in combination with nisin. Moreover, incorporation of both AMPs in a guar gum delivery system (dual-AMP biogel) did not affect the dual-AMP antimicrobial activity. Importantly, the application of the dual-AMP biogel resulted in the eradication of the S. aureus strain from the model. In conclusion, data suggest that the local application of the dual-AMPs biogel constitutes a potential complementary therapy for the treatment of infected DFU.
format Online
Article
Text
id pubmed-7148459
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-71484592020-04-21 Pexiganan in Combination with Nisin to Control Polymicrobial Diabetic Foot Infections Gomes, Diana Santos, Raquel S. Soares, Rui Reis, Solange Carvalho, Sandra Rego, Pedro C. Peleteiro, Maria Tavares, Luís Oliveira, Manuela Antibiotics (Basel) Article Diabetic foot ulcers (DFUs) are major complications of Diabetes mellitus being responsible for significant morbidity and mortality. DFUs frequently become chronically infected by a complex community of bacteria, including multidrug-resistant and biofilm-producing strains of Staphylococcus aureus and Pseudomonas aeruginosa. Diabetic foot infections (DFI) are often recalcitrant to conventional antibiotics and alternative treatment strategies are urgently needed. Antimicrobial Peptides (AMPs), such as pexiganan and nisin, have been increasingly investigated and reported as effective antimicrobial agents. Here, we evaluated the antibacterial potential of pexiganan and nisin used in combination (dual-AMP) to control the growth of planktonic and biofilm co-cultures of S. aureus and P. aeruginosa clinical strains, co-isolated from a DFU. A DFU collagen three-dimensional (3D) model was used to evaluate the distribution and efficacy of AMPs locally delivered into the model. The concentration of pexiganan required to inhibit and eradicate both planktonic and biofilm-based bacterial cells was substantially reduced when used in combination with nisin. Moreover, incorporation of both AMPs in a guar gum delivery system (dual-AMP biogel) did not affect the dual-AMP antimicrobial activity. Importantly, the application of the dual-AMP biogel resulted in the eradication of the S. aureus strain from the model. In conclusion, data suggest that the local application of the dual-AMPs biogel constitutes a potential complementary therapy for the treatment of infected DFU. MDPI 2020-03-20 /pmc/articles/PMC7148459/ /pubmed/32244862 http://dx.doi.org/10.3390/antibiotics9030128 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Gomes, Diana
Santos, Raquel
S. Soares, Rui
Reis, Solange
Carvalho, Sandra
Rego, Pedro
C. Peleteiro, Maria
Tavares, Luís
Oliveira, Manuela
Pexiganan in Combination with Nisin to Control Polymicrobial Diabetic Foot Infections
title Pexiganan in Combination with Nisin to Control Polymicrobial Diabetic Foot Infections
title_full Pexiganan in Combination with Nisin to Control Polymicrobial Diabetic Foot Infections
title_fullStr Pexiganan in Combination with Nisin to Control Polymicrobial Diabetic Foot Infections
title_full_unstemmed Pexiganan in Combination with Nisin to Control Polymicrobial Diabetic Foot Infections
title_short Pexiganan in Combination with Nisin to Control Polymicrobial Diabetic Foot Infections
title_sort pexiganan in combination with nisin to control polymicrobial diabetic foot infections
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7148459/
https://www.ncbi.nlm.nih.gov/pubmed/32244862
http://dx.doi.org/10.3390/antibiotics9030128
work_keys_str_mv AT gomesdiana pexigananincombinationwithnisintocontrolpolymicrobialdiabeticfootinfections
AT santosraquel pexigananincombinationwithnisintocontrolpolymicrobialdiabeticfootinfections
AT ssoaresrui pexigananincombinationwithnisintocontrolpolymicrobialdiabeticfootinfections
AT reissolange pexigananincombinationwithnisintocontrolpolymicrobialdiabeticfootinfections
AT carvalhosandra pexigananincombinationwithnisintocontrolpolymicrobialdiabeticfootinfections
AT regopedro pexigananincombinationwithnisintocontrolpolymicrobialdiabeticfootinfections
AT cpeleteiromaria pexigananincombinationwithnisintocontrolpolymicrobialdiabeticfootinfections
AT tavaresluis pexigananincombinationwithnisintocontrolpolymicrobialdiabeticfootinfections
AT oliveiramanuela pexigananincombinationwithnisintocontrolpolymicrobialdiabeticfootinfections